Grifols to Build Prod. Facility for Intravenous Solutions in Nigeria
Grifols (GRFS) on Monday said that it will construct an intravenous solutions production plant in Nigeria for Dozie and Dozie’s Pharma Nig Ltd., a distributor of healthcare products in the country and surrounding region.
The facility, which is expected to become operational in 2024, will produce as many as 5.5 million intravenous solutions bags yearly to be used in hospitals and other healthcare institutions, according to the company.
Meanwhile, the deal’s financial terms were not disclosed.
When completed in 2024 in southeast Nigeria, the manufacturing installation’s initial phase will produce as many as 5.5 million intravenous solutions bags yearly to be used in hospitals and other healthcare institutions in Nigeria and other African countries.
Read Also: Declining demand for Pharma-Deko products widen loss
With broad global experience building advanced, specialized production facilities for the healthcare and biotechnology sectors, Grifols will design the plant and provide clean rooms and process equipment.
Sufficient capacity will be incorporated to enable the doubling of output to meet the expected growth in demand.
‘Grifols is extremely pleased to be selected by Dozie and Dozie’s Pharma for a state-of-the-art IV solutions manufacturing plant to enhance healthcare delivery in Nigeria and Western Africa,’ said Daniel Fleta, Grifols Chief Industrial Officer.
‘This plant is the latest demonstration of our ongoing commitment to providing high-quality medicines and healthcare solutions to meet the growing needs of the region,’ stated Chidi Dozie, CEO of Dozie and Dozie’s Pharma Nig Ltd., which currently distributes Grifols plasma-derived therapies.
Grifols strengthened its presence in Africa when in November 2020 it entered into a key strategic alliance with the government of Egypt to develop the local market for plasma-derived therapies, including the opening of 20 plasma centres and the construction of a plasma fractionation plant and purification and fill-and-finish plant.
Africa will benefit from this advanced infrastructure aimed at strengthening regional self-sufficiency in hemoderivatives.
The company has also designed and established a plasma collection centre and modular laboratories in Liberia as part of efforts to combat Ebola and is completing an IV solutions plant designed and equipped in Morocco.
Grifols to Build Prod. Facility for Intravenous Solutions in Nigeria
